Medicine and Dentistry
Vasculotropin
50%
Patient
33%
Overall Survival
25%
Progression Free Survival
25%
Bevacizumab
16%
Enalapril Maleate
16%
Regorafenib
16%
Analysis
16%
Placebo
16%
Vasculotropin Inhibitor
16%
Biological Marker
8%
Toxicity
8%
Health Care Cost
8%
Phosphotransferase Inhibitor
8%
Mechanism of Action
8%
Inpatient
8%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Overall Survival
25%
Progression Free Survival
25%
Clinical Study
25%
Phase I Trials
25%
Prospective Study
25%
Bevacizumab
16%
Regorafenib
16%
Kinase
8%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
50%
Metastatic Colorectal Cancer
41%
Overall Survival
25%
Progression Free Survival
25%
Bevacizumab
16%
Enalapril Maleate
16%
Vasculotropin Inhibitor
16%
Regorafenib
16%
Biological Marker
8%
Toxicity
8%
Phosphotransferase Inhibitor
8%
Neuroscience
Bevacizumab
16%
Vasculotropin Inhibitor
16%
Regorafenib
16%
Kinase
8%
Placebo
8%